IN THE CLAIMS

Please amend claims 15 and 20 and cancel claim 16.

1-14 (cancelled)

- 15. (currently amended) A method of making a Type II restriction endonuclease having an altered specificity; comprising:
- (a) selecting a restriction endonuclease characterized by a modular structure having a specificity subunit and a catalytic subunit, the specificity subunit further comprising an N-terminal domain for binding one half site of a bipartite recognition sequence and a C-terminal domain for binding a second half site of the bipartite recognition sequence;
 - (b) modifying the specificity subunit; and
- (c) obtaining the Type II restriction endonuclease with altered specificity.

16. (cancelled)

- 17. (previously presented) A method according to claim 15, wherein modifying the specificity subunit in step (b) further comprises substituting the N-terminal domain with a second C-terminal domain or substituting the C-terminal domain with a second N-terminal domain.
- 18. (previously presented) A method according to claim 15, wherein modifying the specificity subunit further comprises substituting the N-terminal domain or the C-terminal domain or both N-terminal and C-terminal domain with a binding domain from a second restriction endonuclease or methyltransferase.

Docket No. NEB-241-PUS S/N 10/593,790 Page 3

- 19. (previously presented) A method according to claim 15, wherein modifying the specificity subunit further comprises mutating the N-terminal domain, the C-terminal domain or both domains to alter the binding specificity.
- 20. (currently amended) A method according to claim 15, 16, 17, 18 or 19, wherein modifying the specificity subunit further comprises changing the a length of the a spacer amino acid sequence between the N-terminal and C-terminal domains of the specificity module.
- 21. (previously presented) A method according to claim 18, wherein the second restriction endonuclease or methyltransferase is selected from a group consisting of a Type I restriction endonuclease, a Type IIG restriction endonuclease and a γ -type m⁶A methyltransferase.
- 22. (previously presented) A method according to claim 15, wherein the specificity subunit and the catalytic subunit are encoded by different genes.
- 23. (withdrawn) A substantially pure Type IIG restriction endonuclease obtainable from *Citrobacter* species 2144 (NEB#1398) (ATCC Patent Accession No. PTA-5846) or from *Escherichia coli* NEB#1554 (ATCC Patent Accession No. PTA-5887) capable of recognizing at least one sequence selected from the group consisting of SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 and SEQ ID NO:35, and cleaving the DNA on both sides of the recognition sequence.

Docket No. NEB-241-PUS S/N 10/593,790 Page 4

- 24. (withdrawn) An isolated DNA encoding CstMI restriction endonuclease obtainable from *Escherichia coli* NEB#1554 (ATCC Patent Accession No. PTA-5887) or from *Citrobacter* species 2144 (NEB#1398) (ATCC Patent Accession No. PTA-5846).
- 25. (withdrawn) Isolated DNA encoding the restriction endonuclease of claim 1, wherein the DNA comprises a first DNA segment encoding an endonuclease and methyl transferase catalytic function and a second DNA segment encoding a sequence specificity function of the restriction endonuclease wherein the first and second DNA segments comprise one or more DNA molecules.
- 26. (withdrawn) A recombinant DNA vector, comprising: at least one of a first DNA segment coding for the restriction and modification domains of CspCI restriction endonuclease and a second segment coding for the specificity domain of the restriction endonuclease.
- 27. (withdrawn) A host cell transformed with a first DNA segment coding for the restriction and modification domains of CspCI restriction endonuclease and a second segment coding for the specificity domain of the restriction endonuclease wherein the first DNA segment and the second DNA segment are contained within one or more DNA vectors.
- 28. (withdrawn) A method for obtaining the endonuclease of claim 23, comprising cultivating a sample of *Citrobacter* species 2144 (NEB#1398) or a host cell according to claim 6 under conditions favoring the production of the endonuclease; and purifying the endonuclease therefrom.